Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGLRA1GLRBKCNK10KCNK18KCNK2KCNK3KCNK9
The experimentally established mechanism targets of Halothane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halothane SCHEMBL443681 | 1.00 | — | — | |
| Halothane SCHEMBL337605 | 1.00 | — | — | |
| Halothane SCHEMBL25588 | 1.00 | — | — | |
| Halothane SCHEMBL1295253 | 0.96 | — | — | |
| Halothane SCHEMBL5961792 | 0.96 | HSD17B10 (0.92) | HSD17B10ALDH1A1MEN1KMT2A | |
| Halothane SCHEMBL15475924 | 0.92 | — | — | |
| Halothane SCHEMBL6289622 | 0.92 | — | — | |
| Halothane SCHEMBL8902191 | 0.89 | HSD17B10 (0.79) | HSD17B10ALDH1A1MEN1KMT2A | |
| Halothane SCHEMBL10725043 | 0.89 | — | — | |
| Halothane SCHEMBL9138026 | 0.80 | ALDH1A1 (0.65) | HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102006860-B | Pharmaceutical composition containing permethylated cyclodextrin | BROSCHEIT JENS | 2012-12-19 | — | — | CN | disclosed |
| US-20110086037-A1 | METHOD OF TREATING INFLAMMATORY DISORDERS | ILIICH EPSHTEIN OLEG | 2011-04-14 | — | — | US | disclosed |
| CN-102006860-A | Pharmaceutical composition containing permethylated cyclodextrin | JENS BROSCHEIT | 2011-04-06 | — | — | CN | disclosed |
| US-20080081801-A1 | PORPHYRIN OXYGEN INFUSION FOR INCREASING CONCENTRATIONS IN TUMOR TISSUES | TSUCHIDA EISHUN | 2008-04-03 | — | — | US | disclosed |
| US-20050222116-A1 | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | NIPRO CORPORATION (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1512399-A1 | PORPHYRIN OXYGEN INFUSION PREPARATION FOR INCREASING OXYGEN CONCENTRATION IN TUMOR TISSUE | Nipro Corporation (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-5173432-A | Apparatus and method for measuring the concentration or partial pressure of oxygen | THE DOW CHEMICAL COMPANY (US) | 1992-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081801-A1 | PORPHYRIN OXYGEN INFUSION FOR INCREASING CONCENTRATIONS IN TUMOR TISSUES | ALB, PPOX, PPIF | HSD17B10 3402/4885ALDH1A1 2830/4885MEN1 1849/4885 |
| US-20050222116-A1 | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | ALB, PPOX, PPIF | HSD17B10 3670/4885ALDH1A1 3147/4885MEN1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.